The Influence of Number of High Risk Factors on Clinical Outcomes in Patients with Early-stage Cervical Cancer After Radical Hysterectomy and Adjuvant Chemoradiation

Overview

Journal Obstet Gynecol Sci

Specialty Gynecology & Obstetrics

Date 2016 May 21

PMID 27200308

Citations 4

Authors

Soyi Lim

Seok-Ho Lee

Kwang Beom Lee

Chan-Yong Park

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to evaluate the prognosis according to the number of high risk factors in patients with high risk factors after radical hysterectomy and adjuvant chemoradiation therapy for early stage cervical cancer.

Methods: Clinicopathological variables and clinical outcomes of patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB1 to IIA cervical cancer who had one or more high risk factors after radical hysterectomy and adjuvant chemoradiation therapy were retrospectively analyzed. Patients were divided into two groups according to the number of high risk factors (group 1, single high risk factor; group 2, two or more high risk factors).

Results: A total of 93 patients were enrolled in the present study. Forty nine out of 93 (52.7%) patients had a single high risk factor, and 44 (47.3%) had two or more high risk factors. Statistically significant differences in stage and stromal invasion were observed between group 1 and group 2. However, age, histology, tumor size, and lymphovascular space invasion did not differ significantly between the groups. Distant recurrence occurred more frequently in group 2, and the probability of recurrence and death was higher in group 2.

Conclusion: Patients with two or more high risk factors had worse prognosis in early stage cervical cancer. For these patients, consideration of new strategies to improve survival may be worthwhile. Conduct of further clinical trials is warranted for development of adjuvant treatment strategies individualized to each risk group.

Citing Articles

Cervical Cancer Stages, Human Papillomavirus Integration, and Malignant Genetic Mutations: Integrative Analysis of Datasets from Four Different Cohorts.

Mohammed F, Tune K, Jett M, Muhie S Cancers (Basel). 2023; 15(23).

PMID: 38067297 PMC: 10705285. DOI: 10.3390/cancers15235595.

Prognostic Factors Analysis of Metastatic Recurrence in Cervical Carcinoma Patients Treated with Definitive Radiotherapy: A Retrospective Study Using Mixture Cure Model.

Ou X, You J, Liang B, Li X, Zhou J, Wen F Cancers (Basel). 2023; 15(11).

PMID: 37296875 PMC: 10252127. DOI: 10.3390/cancers15112913.

Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study.

Li J, Liu G, Luo J, Yan S, Ye P, Wang J Sci Rep. 2022; 12(1):13994.

PMID: 35978078 PMC: 9385852. DOI: 10.1038/s41598-022-17733-8.

Prognostic Factors Associated with 5-Year Overall Survival in Cervical Cancer Patients Treated with Radical Hysterectomy Followed by Adjuvant Concurrent Chemoradiation Therapy at a Tertiary Care Center in Eastern Europe.

Stanca M, Capilna M Diagnostics (Basel). 2021; 11(3).

PMID: 33810019 PMC: 8005151. DOI: 10.3390/diagnostics11030570.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Peters 3rd W, Liu P, Barrett 2nd R, STOCK R, Monk B, Berek J . Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18(8):1606-13. DOI: 10.1200/JCO.2000.18.8.1606. View

Lai C, Chang H, Chang T, Hsueh S, Tang S . Prognostic factors and impacts of adjuvant therapy in early-stage cervical carcinoma with pelvic node metastases. Gynecol Oncol. 1993; 51(3):390-6. DOI: 10.1006/gyno.1993.1309. View

Eifel P, Winter K, Morris M, Levenback C, Grigsby P, Cooper J . Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004; 22(5):872-80. DOI: 10.1200/JCO.2004.07.197. View

Aoki Y, Sasaki M, Watanabe M, Sato T, Tsuneki I, Aida H . High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Gynecol Oncol. 2000; 77(2):305-9. DOI: 10.1006/gyno.2000.5788. View

Iwasaka T, Kamura T, Yokoyama M, Matsuo N, Nakano H, Sugimori H . Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of adjuvant radiotherapy. Obstet Gynecol. 1998; 91(6):977-81. DOI: 10.1016/s0029-7844(98)00079-9. View

Alvarez R, Soong S, Kinney W, Reid G, Schray M, Podratz K . Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol. 1989; 35(2):130-5. DOI: 10.1016/0090-8258(89)90029-2. View

Lahousen M, Haas J, Pickel H, Hackl A, Kurz C, Ogris H . Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial. Gynecol Oncol. 1999; 73(2):196-201. DOI: 10.1006/gyno.1999.5343. View

Kodama J, Seki N, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y . Prognostic factors in node-positive patients with stage IB-IIB cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy. Int J Gynaecol Obstet. 2006; 93(2):130-5. DOI: 10.1016/j.ijgo.2006.02.012. View

10.

Suprasert P, Srisomboon J, Kasamatsu T . Radical hysterectomy for stage IIB cervical cancer: a review. Int J Gynecol Cancer. 2005; 15(6):995-1001. DOI: 10.1111/j.1525-1438.2005.00259.x. View

11.

Wertheim M, Hakes T, Daghestani A, Nori D, Smith D, Lewis Jr J . A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 1985; 3(7):912-6. DOI: 10.1200/JCO.1985.3.7.912. View

12.

Tattersall M, Ramirez C, Coppleson M . A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases. Gynecol Oncol. 1992; 46(2):176-81. DOI: 10.1016/0090-8258(92)90251-d. View

13.

Van Nagel Jr J, Donaldson E, Parker J, Van Dyke A, Wood E . The prognostic significance of cell type and lesion size in patients with cervical cancer treated by radical surgery. Gynecol Oncol. 1977; 5(2):142-51. DOI: 10.1016/0090-8258(77)90018-x. View

14.

Uno T, Ito H, Itami J, Yasuda S, Isobe K, Hara R . Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors. Anticancer Res. 2000; 20(3B):2235-9. View

15.

. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26(35):5802-12. PMC: 2645100. DOI: 10.1200/JCO.2008.16.4368. View

16.

Park J, Kim D, Kim J, Kim Y, Kim Y, Nam J . Further stratification of risk groups in patients with lymph node metastasis after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol. 2010; 117(1):53-8. DOI: 10.1016/j.ygyno.2009.12.006. View

17.

Samlal R, Velden J, Schilthuis M, Gonzalez Gonzalez D, Ten Kate F, Hart A . Identification of high-risk groups among node-positive patients with stage IB and IIA cervical carcinoma. Gynecol Oncol. 1997; 64(3):463-7. DOI: 10.1006/gyno.1996.4576. View

18.

Winter R, Haas J, Reich O, Koemetter R, Tamussino K, Lahousen M . Parametrial spread of cervical cancer in patients with negative pelvic lymph nodes. Gynecol Oncol. 2002; 84(2):252-7. DOI: 10.1006/gyno.2001.6495. View

19.

Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P . Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350(9077):535-40. DOI: 10.1016/S0140-6736(97)02250-2. View

20.

Delgado G, Bundy B, Zaino R, Sevin B, Creasman W, Major F . Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990; 38(3):352-7. DOI: 10.1016/0090-8258(90)90072-s. View